$GNPX Undervalued by at least 300% at its current trial phase. SP should be pushing $5 with a 5-6X move on positive findings of Phase 2 testing with Keytruda and Tagrisso. And, if Gittes can ever move the diabetes treatment into an FDA fast track trial, double it again. If GNPX has a viable diabetes treatment, ten-bag that.
2
1
11
11 Likes